Understanding PD Prevalence
Understanding how many people are living with PD is critical to advancing research and care. To address it, PDF is investing $250,000 in the PD Prevalence Project.Learn More
Your Donations Make a Difference
Your support makes the research of Dr. Hess and Dr. Earhart possible, allowing us to learn about the role of genetics and the potential of exercise in Parkinson's.
Watch Our Video & Learn More
FDA Approves Nuplazid™ for Treatment of Psychosis in Parkinson’s
May 3, 2016
The Parkinson’s Disease Foundation (PDF) alerts the community that pimavanserin (Nuplazid™) has been approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug’s manufacturer, Acadia Pharmaceuticals Inc., announced the approval on April 29. Pimavanserin is the first drug indicated specifically to treat symptoms of psychosis in Parkinson’s.
Annual Gala - Bal du Printemps
Wednesday, May 11 (New York, NY)
Join PDF and Co-Chairs Jill Taub Drury, Stephanie Goldman-Pittel, Karen Burke Goulandris, M.D., Ph.D., Isobel Robins Konecky and Arlene Levine for a gala to benefit Parkinson's research at The Metropolitan Club. The evening will honor top-performing PDF Champions whose efforts as volunteer fundraisers have helped the program to raise $2.5 million and will include Master of Ceremonies Willie Geist, Host of NBC’s “Sunday TODAY with Willie Geist,” Co-host of NBC News’ “Today” and Co-host of MSNBC’s “Morning Joe.”